Sunday, 25 February 2024

Australia's most trusted
source of pharma news

Sunday, 25 February 2024
Listen to this story 

Sandoz strikes new five-year deal

 Posted 12 February 2024 AM

Sandoz has announced a new five-year partnership with Biocon Biologics for the exclusive rights to promote, sell and distribute biosimilar versions of two top Roche cancer drugs Herceptin and Avastin in Australia.

Under the deal Sandoz will distribute the Biocon brands, Ogivri, a Herceptin biologic and Abvemy, an Avastin biologic, which the company said had previously been distributed by another pharma. According to the ARTG, the sponsor for Ogivri was Maxx Pharma. 

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (16)

Clinical & Medical, R&D (11)

Regulatory, Pharmacovigilance & QA (7)

Other (26)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.